Andrew Hill

1.8k total citations
38 papers, 1.1k citations indexed

About

Andrew Hill is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Andrew Hill has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Infectious Diseases, 26 papers in Virology and 8 papers in Epidemiology. Recurrent topics in Andrew Hill's work include HIV/AIDS drug development and treatment (29 papers), HIV Research and Treatment (26 papers) and HIV/AIDS Research and Interventions (23 papers). Andrew Hill is often cited by papers focused on HIV/AIDS drug development and treatment (29 papers), HIV Research and Treatment (26 papers) and HIV/AIDS Research and Interventions (23 papers). Andrew Hill collaborates with scholars based in United Kingdom, Germany and Netherlands. Andrew Hill's co-authors include Anton Pozniak, Jacob Levi, Philipp Köhler, Anthony Sawyer, Ravindra K. Gupta, Christiane Moecklinghoff, Pietro Vernazza, Deenan Pillay, José Ramón Arribas and Yvon van Delft and has published in prestigious journals such as Clinical Infectious Diseases, Gut and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Andrew Hill

37 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Hill United Kingdom 16 892 579 311 255 114 38 1.1k
Paola Meraviglia Italy 19 941 1.1× 556 1.0× 368 1.2× 330 1.3× 113 1.0× 61 1.3k
Marco Floridia Italy 19 935 1.0× 373 0.6× 362 1.2× 334 1.3× 115 1.0× 99 1.2k
Peter Gute Germany 18 868 1.0× 688 1.2× 308 1.0× 216 0.8× 41 0.4× 35 1.2k
JN Bruun United States 5 937 1.1× 625 1.1× 380 1.2× 300 1.2× 24 0.2× 6 1.1k
Stephen E. Van Rompaey United States 11 503 0.6× 184 0.3× 283 0.9× 268 1.1× 21 0.2× 15 818
Stéphane Blanche France 16 624 0.7× 270 0.5× 362 1.2× 171 0.7× 103 0.9× 32 1.0k
Lerato Mohapi South Africa 20 1.2k 1.4× 467 0.8× 684 2.2× 160 0.6× 143 1.3× 35 1.5k
Montserrat Loncà Spain 19 868 1.0× 423 0.7× 521 1.7× 414 1.6× 109 1.0× 44 1.4k
Rachael Jones United Kingdom 20 816 0.9× 279 0.5× 240 0.8× 464 1.8× 67 0.6× 65 1.2k
Bingxia Wang United States 21 1.0k 1.1× 435 0.8× 675 2.2× 101 0.4× 91 0.8× 56 1.6k

Countries citing papers authored by Andrew Hill

Since Specialization
Citations

This map shows the geographic impact of Andrew Hill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Hill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Hill more than expected).

Fields of papers citing papers by Andrew Hill

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Hill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Hill. The network helps show where Andrew Hill may publish in the future.

Co-authorship network of co-authors of Andrew Hill

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Hill. A scholar is included among the top collaborators of Andrew Hill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Hill. Andrew Hill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hill, Andrew, Simiso Sokhela, Bryony Simmons, et al.. (2024). Low CD4 counts predict excessive weight gains during first-line treatment for HIV. Journal of Antimicrobial Chemotherapy. 79(9). 2369–2378. 4 indexed citations
2.
3.
Pepperrell, Toby, et al.. (2024). Lower Prevalence Countries Outside of South-Eastern Africa Now Have the Fastest Growing HIV Epidemic. Open Forum Infectious Diseases. 11(7). ofae318–ofae318. 1 indexed citations
4.
Yakoot, Mostafa, et al.. (2020). Efficacy and Safety of Sofosbuvir/Daclatasvir in the Treatment of COVID-19: A Randomized, Controlled Study. SSRN Electronic Journal. 2 indexed citations
5.
Gotham, Dzintars, Joseph Fortunak, Anton Pozniak, et al.. (2016). Estimated generic prices for novel treatments for drug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy. 72(4). dkw522–dkw522. 20 indexed citations
6.
7.
Perri, Giovanni Di, Bruce Green, Glynn Morrish, et al.. (2013). Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-Naïve Patients. HIV Clinical Trials. 14(3). 92–98. 5 indexed citations
8.
Colombo, M., Inmaculada Fernández, Paulo Roberto Abrão Ferreira, et al.. (2013). Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Gut. 63(7). 1150–1158. 42 indexed citations
9.
Stephan, Christoph, Andrew Hill, W. A. Sawyer, Yvon van Delft, & Christiane Moecklinghoff. (2012). Impact of baseline HIV‐1 RNA levels on initial highly active antiretroviral therapy outcome: a meta‐analysis of 12,370 patients in 21 clinical trials*. HIV Medicine. 14(5). 284–292. 22 indexed citations
10.
Sultan, Binta, et al.. (2011). Prevalence of drug resistance in untreated HIV-1-infected individuals in low- and middle-income countries: a systematic review and meta-analysis. UCL Discovery (University College London). 1 indexed citations
11.
Fox, Julie, et al.. (2010). Improvement in Vitamin D Deficiency Following Antiretroviral Regime Change: Results from the MONET Trial. AIDS Research and Human Retroviruses. 27(1). 29–34. 69 indexed citations
12.
Gazzard, Brian, et al.. (2010). Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review.. PubMed. 12(2). 67–75. 35 indexed citations
13.
Hill, Andrew, et al.. (2009). Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries. Current Opinion in HIV and AIDS. 5(1). 90–96. 6 indexed citations
14.
Arribas, José Ramón, Andrzéj Horban, Jan Gerstoft, et al.. (2009). The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 24(2). 223–230. 140 indexed citations
15.
Ananworanich, Jintanat, Reto Nüesch, Hélène C. F. Côté, et al.. (2008). Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy. Journal of Antimicrobial Chemotherapy. 61(6). 1340–1343. 30 indexed citations
16.
Autar, Reshma, Ferdinand W N M Wit, Elly A. Hassink, et al.. (2007). Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. AIDS. 21(12). 1535–1539. 8 indexed citations
17.
Boffito, Marta, Laura Dickinson, David Back, et al.. (2006). Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir and Atazanavir When Combined Once Daily in HIV Type 1-Infected Individuals Administered Different Atazanavir Doses. AIDS Research and Human Retroviruses. 22(8). 749–756. 11 indexed citations
18.
Ananworanich, Jintanat, Pope Kosalaraksa, Andrew Hill, et al.. (2005). Pharmacokinetics and 24-Week Efficacy/Safety of Dual Boosted Saquinavir/Lopinavir/Ritonavir in Nucleoside-Pretreated Children. The Pediatric Infectious Disease Journal. 24(10). 874–879. 40 indexed citations
19.
Moyle, Graeme, Will Sawyer, Matthew Law, Janaki Amin, & Andrew Hill. (2004). Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: A meta-analysis of six prospective, randomized, comparative studies. Clinical Therapeutics. 26(1). 92–97. 65 indexed citations
20.
Gompels, Mark, Andrew Hill, Paul Jenkins, et al.. (1992). Kaposiʼs sarcoma in HIV infection treated with vincristine and bleomycin. AIDS. 6(10). 1175–1180. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paola Meraviglia Breakdown of academic impact, for papers by Marco Floridia Breakdown of academic impact, for papers by Peter Gute Breakdown of academic impact, for papers by JN Bruun Breakdown of academic impact, for papers by Stephen E. Van Rompaey Breakdown of academic impact, for papers by Stéphane Blanche Breakdown of academic impact, for papers by Lerato Mohapi Breakdown of academic impact, for papers by Montserrat Loncà Breakdown of academic impact, for papers by Rachael Jones Breakdown of academic impact, for papers by Bingxia Wang
Rankless by CCL
2026